Drug Trial Radar · NCT06048484
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
May 10, 2024
Primary completion
Apr 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- Gulam ManjiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Arcus Biosciences, Inc.
- First posted
- Sep 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to combine standard radiation therapy with drugs that encourages the body's immune system against cancer cells and simultaneously adding drugs which also target the pathway that the tumor uses to evade the immune system (CD73 and A2a/b). The study hopes that these drugs will work in concert with radiation therapy to kill cancer cells. The specific goal of this study is to ensure that treatment with zimberelimab and stereotactic body radiation therapy (SBRT) alone or in combination with quemliclustat (a drug which blocks CD73), with or without etrumadenant (a drug which blocks the A2a/b) given before surgery is safe and if it can further increase the immune response against the tumor.
Conditions
- Pancreatic Ductal Adenocarcinoma
Interventions
Stereotactic body radiotherapy (SBRT)Radiation
SBRT 40 gray (Gy) over 5 fractions
ZimberelimabDrug
240 mg intravenously (IV)
QuemliclustatDrug
100 mg IV
EtrumadenantDrug
150 mg orally
Modified FOLFIRINOXDrug
* Oxaliplatin 85 mg per square meter IV * Irinotecan 150 mg per square meter IV * Leucovorin 400 mg per square meter IV * Fluorouracil 2400 mg per square meter IV * Pegfilgrastim injector kit (6mg subcutaneous)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the number of intratumoral CD8+ T-cellsTime frame: Perioperative
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Northwell Health R.J. Zuckerberg Cancer Center
Lake Success, New York · Recruiting
Columbia University Irving Medical Center
New York, New York · Recruiting
UNC Hospitals, The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.